Skip to content

Study · Randomized controlled trial · 2009

4 results

Relative effects of estrogen, age, and visceral fat on pulsatile growth hormone secretion in healthy women.

Veldhuis JD, Hudson SB, Erickson D, Bailey JN, Reynolds GA, Bowers CY

American journal of physiology. Endocrinology and metabolism26 May 2009Cited by 14 (Europe PMC)

PMID19470834 (opens in a new tab)PMCIDPMC2724113 (opens in a new tab)DOI10.1152/ajpendo.00230.2009 (opens in a new tab)PepBankPUB-19470834
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    Independent of estradiol status, postmenopausal women had a lower GH response to GHRP‑2 than premenopausal women (P < 0.001).

    In plain wordsOlder postmenopausal women had a weaker GH response to GHRP‑2 than premenopausal women.

    Peptide
    GHRP-2
    Outcome
    DecreaseGH response to GHRP-2 in postmenopausal versus premenopausal women
    Study

    n: not reported in source

    Comparator
    Premenopausal women
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intravenous · continuous infusionAs given in this study (human).

    Source sentences

    Summary
    Independently of E(2) status, POST women had lower GH responses to both GHRH (P = 0.028) and GHRP-2 (P < 0.001) than PRE women.
    1 context sentence
    Summary · context
    To this end, healthy PRE (n = 20) and POST (n = 22) women underwent a low- vs. high-E(2) clamp before receiving a continuous intravenous infusion of GH-releasing hormone (GHRH) or GH-releasing peptide (GHRP-2).
  2. 02HumanRandomized controlled trialEfficacy outcome

    Independent of age, GHRP‑2 was more stimulatory of GH than GHRH during low estradiol (P = 0.011).

    In plain wordsAt low estradiol, GHRP‑2 raised GH more than GHRH did.

    Peptide
    GHRP-2
    Outcome
    IncreaseGHRP-2 versus GHRH stimulation of GH at low estradiol
    Study

    n: not reported in source

    Comparator
    GHRH
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intravenous · continuous infusionAs given in this study (human).

    Source sentences

    Summary
    Independently of age, GHRP-2 was more stimulatory than GHRH during low E(2) (P = 0.011)
    1 context sentence
    Summary · context
    To this end, healthy PRE (n = 20) and POST (n = 22) women underwent a low- vs. high-E(2) clamp before receiving a continuous intravenous infusion of GH-releasing hormone (GHRH) or GH-releasing peptide (GHRP-2).
  3. 03HumanRandomized controlled trialEfficacy outcome

    Independent of age, GHRP‑2 was more stimulatory of GH than GHRH during high estradiol (P < 0.001).

    In plain wordsAt high estradiol, GHRP‑2 raised GH more than GHRH did.

    Peptide
    GHRP-2
    Outcome
    IncreaseGHRP-2 versus GHRH stimulation of GH at high estradiol
    Study

    n: not reported in source

    Comparator
    GHRH
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intravenous · continuous infusionAs given in this study (human).

    Source sentences

    Summary
    Independently of age, GHRP-2 was more stimulatory than GHRH during low E(2) (P = 0.011) and high E(2) (P < 0.001).
    1 context sentence
    Summary · context
    To this end, healthy PRE (n = 20) and POST (n = 22) women underwent a low- vs. high-E(2) clamp before receiving a continuous intravenous infusion of GH-releasing hormone (GHRH) or GH-releasing peptide (GHRP-2).
  4. 04HumanRandomized controlled trialMechanism

    Age and estradiol together explained 60% of the variability in the GH response to GHRP‑2 (P < 0.001).

    In plain wordsAge and estradiol together explained most of the differences between women in the GH response to GHRP‑2.

    Peptide
    GHRP-2
    Outcome
    Not applicableVariability of GHRP-2 drive explained by age and estradiol
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intravenous · continuous infusionAs given in this study (human).

    Measurements

    Variability explained
    60%
    age and E2 together

    Source sentences

    Summary
    age and E(2) together explained 60% of the variability in GHRP-2 drive (P < 0.001)
    1 context sentence
    Summary · context
    To this end, healthy PRE (n = 20) and POST (n = 22) women underwent a low- vs. high-E(2) clamp before receiving a continuous intravenous infusion of GH-releasing hormone (GHRH) or GH-releasing peptide (GHRP-2).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.